logo

Spero Therapeutics, Inc. (SPRO)



Trade SPRO now with
  Date
  Headline
2/5/2021 8:19:20 AM Spero Therapeutics Says FDA Placed Clinical Hold On Phase 2a Clinical Trial Of SPR720
12/17/2020 8:12:43 AM Spero Therapeutics Appoints Sath Shukla As CFO
11/3/2020 8:37:40 AM Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/11/2020 7:03:25 AM Spero Therapeutics Reports Pricing Of Securities Offering For Gross Proceeds Of $80.0 Mln
9/8/2020 7:41:21 AM Spero Therapeutics Announces Positive Topline Results From Phase 3 ADAPT-PO Clinical Trial Of Oral Tebipenem HBr
8/31/2020 8:03:47 AM Spero Therapeutics Announces FDA Acceptance Of IND Application For SPR720 For NTM Pulmonary Disease
6/1/2020 7:48:00 AM Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/16/2020 8:43:17 AM Spero Appoints Scott Jackson To Its Board
3/11/2020 8:36:05 AM Spero Therapeutics Says FDA Granted Orphan Drug Designation For Oral SPR720
10/3/2019 8:05:15 AM Spero Reports Positive Recommendation To Continue Phase 3 Trial Of SPR994
7/16/2019 8:14:45 AM Spero Therapeutics Receives $5.9 Mln Award From DoD
6/13/2019 8:09:57 AM Spero Announces $10 Mln Registered Direct Offering Of Common Stock
3/29/2019 8:12:04 AM Spero Therapeutics Gets FDA Fast Track Designation For SPR994 For CUTI And Acute Pyelonephritis
2/4/2019 7:07:49 AM Spero Therapeutics Announces FDA Acceptance Of IND Application For SPR994
11/5/2018 8:05:28 AM Spero Announces Positive Results From SPR720 IND-Enabling Studies And Plans To Initiate A Phase 1 Trial